Purchase, New York-Based Teladoc Health's Top-Tier Executives Average Annual Pay and Benefits Increase During the Past Three Years Since Its IPO Was an Off-the-Charts 105.4% Per Year

From Company Proxy Statement filings with the SEC, below are Teladoc Health's Top-Tier Executives Annual Total Compensation for each of two consecutive full years of employment for the most recent  three years since its IPO.

	FYE	FYE		FYE	FYE		FYE	FYE
	Dec	Dec		Dec	Dec		Dec	Dec
Teladoc Health	2018	2017		2017	2016		2016	2015
Top-Tier	Total	Total		Total	Total		Total	Total
Executive	Comp	Comp		Comp	Comp		Comp	Comp
	$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s
Jason Gorevic CEO	7,329	7,104		7,104	3,607		3,607	973
Mark Hirschhorn Former CFO	5,578	3,271		3,271	1,208		1,208	773
Peter McClennen President	N/A	N/A
Adam Vandervoort Chief Legal Officer	1,987	1,704		1,704	679		N/A	N/A
Stephany Verstraete Chief Marketing Officer	N/A	N/A
Michael King				1,736	872
Totals	14,894	12,079		13,815	6,366		4,815	1,746
Annual % Change vs Prior Year	23.3%			117.0%			175.8%
Three Year Average Per Year % Change		105.4%

Tarrytown, New York-Based Regeneron Pharmaceuticals' Top-Tier Executives Average Annual Pay and Benefits Increase During the Past Ten Years Was a Blistering 57.0% Per Year

From Company Proxy Statement filings with the SEC, below are Regeneron Pharmaceuticals Inc's Top-Tier Executives Annual Total Compensation for each of two consecutive full years of employment for the most recent ten years.

	FYE	FYE		FYE	FYE		FYE	FYE		FYE	FYE		FYE	FYE
	Dec	Dec		Dec	Dec		Dec	Dec		Dec	Dec		Dec	Dec
Regeneron Pharmaceuticals	2018	2017		2017	2016		2016	2015		2015	2014		2014	2013
Top-Tier	Total	Total		Total	Total		Total	Total		Total	Total		Total	Total
Executive	Comp	Comp		Comp	Comp		Comp	Comp		Comp	Comp		Comp	Comp
	$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s
Schleifer CEO	26,521	26,508		26,508	28,338		28,338	47,463		47,463	41,965		41,965	36,273
Yancopoulos Chief Scientific Officer	25,381	25,299		25,299	27,768		27,768	40,302		40,302	35,507		35,507	31,018
Landry CFO	9,357	4,795		4,795	5,165		5,165	8,249		8,249	7,373		N/A	N/A
Van Plew	9,007	8,979
Stahl EVP R&D				9,137	10,985		10,985	18,375		18,375	16,254		16,254	14,355
Terifay							6,771	11,157		11,157	8,396		8,396	7,679
	70,266	65,581		65,739	72,256		79,027	125,546		125,546	109,495		102,122	89,325
Annual % Change vs Prior Year	7.1%			-9.0%			-37.1%			14.7%			14.3%
5 Year Average Per Year % Change		-2.0%
	FYE	FYE		FYE	FYE		FYE	FYE		FYE	FYE		FYE	FYE
	Dec	Dec		Dec	Dec		Dec	Dec		Dec	Dec		Dec	Dec
Regeneron Pharmaceuticals	2013	2012		2012	2011		2011	2010		2010	2009		2009	2008
Top-Tier	Total	Total		Total	Total		Total	Total		Total	Total		Total	Total
Executive	Comp	Comp		Comp	Comp		Comp	Comp		Comp	Comp		Comp	Comp
	$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s		$ 000s	$ 000s
Schleifer CEO	36,273	30,047		30,047	10,563		10,563	7,588		7,588	6,349		6,349	2,554
Yancopoulos Chief Scientific Officer	31,018	81,551		81,551	10,027		10,027	13,352		13,352	5,108		5,108	1,944
Landry CFO	N/A	N/A
Van Plew
Stahl EVP R&D	14,355	11,995		11,995	3,150		3,150	4,520		4,520	2,867		2,867	1,102
Terifay	7,679	7,478
Goldberg	2,711	9,623		9,623	3,106		3,106	3,638		3,638	2,015		2,015	993
Totals	92,036	140,694		133,216	26,846		26,846	29,098		29,098	16,339		16,339	6,593
Annual % Change vs Prior Year	-34.6%			396.2%			-7.7%			78.1%			147.8%
5 Year Average Per Year % Change		116.0%
5 Year Average Per Year % Change		57.0%